New paper in ACS Biomaterials Science & Engineering

Check out our latest research in ACS Biomaterials Science & Engineering! Michał Żebrowski, MSc, and Prof. Grzegorz Litwinienko, in collaboration with researchers from the University of Rzeszów, CSIC-University of Zaragoza, and the University of Agriculture in Kraków, have developed a nanoplatform consisting of iron oxide nanoparticles functionalized with an antibody targeting the cell surface marker CD26 and loaded with the senolytic drug HSP90 inhibitor 17-DMAG. Our study demonstrated the efficacy of this nanoplatform against oxidative stress-induced senescent human fibroblasts (WI-38 and BJ cells) and anticancer drug-induced senescent cutaneous squamous cell carcinoma (A431 cells). For the first time, we have shown that CD26 is a valid marker of senescence in cancer cells.